Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma

Inclusion Criteria: * Diagnosis of chronic lymphocytic lymphoma or small lymphocytic lymphoma (Phase 1) or relapsed/refractory NHL (Phase 1b) * Previous treatment with at least one fludarabine-containing regimen * Demonstrate at least one of the following criteria for active disease requiring treatment: * a)progressive splenomegaly and/or lymphadenopathy; * b)anemia or thrombocytopenia due to bone marrow involvement; * c)unintentional weight loss \>10% over preceding 6-month period; * d) NCI Grade 2 or 3 fatigue; * e) fevers \>100.5 F or night sweats for \> 2 weeks without infection; * f) progressive lymphocytosis with increase of \>50% over a 2-month period or anticipated doubling time of \< 6 months. * ECOG performance status \</= 2 * SGOT, SGPT \</= 2.0 x upper limit of normal * ANC \>/= 500/uL * Platelets \>/= 30,000/uL * Discontinued previous anticancer or investigational therapy for at least 30 days Exclusion Criteria: * Treatment with rituximab within 30 days or alemtuzumab(Campath)or radioimmune therapy within 12 weeks * ANC \</= 500/uL * Platelets \</= 30,000/mm3 * Previous or concurrent additional malignancy * Significant concurrent medical diseases or conditions * Hepatitis B surface antigen or hepatitis B core antibody positive * Pregnant or breastfeeding